The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
about
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis.How genetic variation affects patient response and outcome to therapy for psoriasis.Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy.Dermatology: future therapeutic perspectives.HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.Toll-like receptor 9 promoter polymorphism as a predictive factor of narrow-band UVB phototherapy response in patients with psoriasis
P2860
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
@ast
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
@en
type
label
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
@ast
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
@en
prefLabel
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
@ast
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
@en
P2860
P1476
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis
@en
P2093
Griffiths CE
P2860
P304
P356
10.1111/J.1365-2133.2005.06880.X
P407
P577
2005-11-01T00:00:00Z